



# Valiant Organics Limited

June 17, 2024

To,  
Listing/Compliance Department  
**BSE LTD**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001.

To,  
Listing/Compliance Department  
**National Stock Exchange of  
India Limited**  
“Exchange Plaza”, Plot No. C/1,  
G Block Bandra-Kurla  
Complex, Bandra (E),  
Mumbai- 400 051

**SCRIP CODE - 540145**

**SYMBOL- VALIANTORG**

**Sub: Investor Presentation**

Dear Sir / Madam,

In continuation of our intimation dated May 31, 2024 and pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Extended Investors' Presentation for Q4 FY24 Results of Valiant Organics Limited.

A copy of aforesaid Investor Presentation is also hosted on the website of company [www.valiantorganics.com](http://www.valiantorganics.com).


Please take the same on your records.

Thanking you.

Yours faithfully,

**For Valiant Organics Limited**


Mahek Chheda  
**Executive Director**  
DIN: 06763870



# Valiant Organics Limited

Investor Presentation | June 2024

# SNAPSHOT



One of the largest chlorophenol derivatives manufacturer globally



One of the leading manufacturer of Benzene derivatives products



One of the largest domestic PNA manufacturer



One of the few commercial players in Ortho Anisidine and Para Anisidine



Amongst 1st few domestic PAP Manufacturers



Diversified client base across Pharmaceuticals, Dyes & Pigments, Agrochemicals and specialty chemicals.



6 Manufacturing units across 5 Locations




5 Zero Liquid Discharge plants



Total Production Capacity of 70,000 TPA




1300+ Employees




# COMPANY OVERVIEW

- Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India.
- The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmaceuticals, dyes, pigments, and veterinary medications.
- Key chemistries include Chlorination, Hydrogenation, Ammonolysis, Acetylation, Sulphonation, Methoxylation amongst others.
- Over the years the company has primarily focused on manufacturing specialty chemicals that have a high demand but low supply and are primarily dependent on imports.
- The company is listed on both the BSE and NSE with a market capitalization of INR ~10,473 Mn. as on 31st March, 2024.


Operating Revenue (INR Mn) and EBITDA Margin (%)



FY24 Revenue Break-up – Chemistries



FY24 Revenue Break-up – End user Industry





Shri Navin C. Shah  
(Chairman & Independent  
Director)



Shri Sathiababu K. Kallada  
(Managing Director)



Shri Mahek M. Chheda  
(Chief Financial Officer &  
Executive Director)



Shri Nemin Savadia  
(Executive Director)



Shri Siddharth Shah  
(Executive Director)



Shri Parimal Hasmukhlal Desai  
(Non-Executive Director)



Shri Santosh S Vora  
(Non-Executive Director)



Dr. Kiritkumar H. Desai  
(Non-Executive Director)



Dr. Sudhirprakash B. Sawant  
(Independent Director)





Shri Mulesh M. Savla  
(Independent Director)




Smt. Sonal A. Vira  
(Independent Director)

# Key Milestones







| Product                  | Project Status       | Remarks   |
|--------------------------|----------------------|---|
| Ongoing Projects         |                      |   |
| Ortho Amino Phenol (OAP) | Expected to commence | <ul style="list-style-type: none"><li>• Currently, entirely imported in India</li><li>• Part of the production will be utilized as forward integration for one of company's existing products</li><li>• Trial run successful however, further improvement is still required</li></ul> |



# BUSINESS OVERVIEW

## FY24 Revenue Share

### Ammonolysis

**Key Products:**

- Para Nitro Aniline
- Ortho Chloro Para Nitro Aniline

**Industries Served:**

- Dyes
- Pigments

### Others

**Acetylation**

**Key Products:**

- 6 Acetyl OAPSA
- OA Acetanilide
- PA Acetanilide

**Industries Served:**

- Dyes

**Sulphonation**

**Key Products:**

- OT5SA
- 4B Acid
- 2B Acid

**Industries Served:**

- Dyes
- Pigments


**Methoxylation**

**Key Products:**

- Ortho Nitro Anisole
- Para Nitro Anisole

**Industries Served:**

- Dyes
- Pigments



### Hydrogenation

**Key Products:**

- Ortho Anisidine
- Para Anisidine
- IPPCA
- Meta Chloro Aniline
- Para Amino Phenol
- Ortho Amino Phenol

**Industries Served:**

- Dyes
- Pigments
- Pharmaceutical
- Agro Chemicals

### Chlorination

**Key Products:**

- Para ChloroPhenol (PCP)
- Ortho ChloroPhenol (OCP)
- 2,4 Di Chlorophenol (2,4 DCP)
- 2,6 Di ChloroPhenol (2,6 DCP)
- 2,4,6 Tri ChloroPhenol (2,4,6 TCP)

**Industries Served:**

- Agro Chemicals
- Cosmetics
- Veterinary
- Pharmaceuticals

Any reaction in which chlorine or chlorine compounds are introduced into a molecule to obtain the desired outcome is known as chlorination.

- Valiant is the only domestic player and also a global leader in Chlorophenol products with ~25% global market share.
- The company has over two-decade experience in Chlorophenols, with long-term relationships with global marquee customers due to their high-quality products and efficient supply chain management.
- The Sarigram plant of the company is dedicated for the chlorination process, with a capacity of 18,000 MTPA, and a Zero Liquid Discharge facility and highly automated Distributed Control Systems significantly reducing manual interventions.
- More than 50% of sales come from export markets.


## Key Products:

- Para ChloroPhenol (PCP)
- Ortho ChloroPhenol (OCP)
- 2,4 Di Chlorophenol (2,4 DCP)
- 2,6 Di ChloroPhenol (2,6 DCP)
- 2,4,6 Tri ChloroPhenol (2,4,6 TCP)


## Industries Served:

- Agro Chemicals
- Cosmetics
- Veterinary
- Pharmaceuticals

## Revenues (INR Mn)\*



## Sales Volumes (MT)



\*Revenue figures are on Standalone basis

Ammonolysis is a high-pressure chemical reaction done in an autoclave where ammonia is used as a reactant.

- Valiant developed Ammonolysis capabilities as a result of its two acquisitions. i.e. Abhilasha Tex Chem Pvt. Ltd. in 2017 & Amarjyot Chemicals Ltd. in 2019.
- The company has an approximately 15,600 MTPA capacity for this process, making it one of the largest players in the domestic market.
- Valiant has two dedicated manufacturing facilities located at Tarapur and Vapi to carry out the ammonolysis process.
- The company supplies its products to almost all the leading Dye manufacturers in the country, and has a leadership position in manufacturing PNA due to its raw material security of PNCB from group company, Aarti Industries.


### Key Products:

- Para Nitro Aniline (PNA)
- Ortho Chloro Para Nitro Aniline


### Industries Served:

- Dyes
- Pigments

### Revenues (INR Mn)\*



### Sales Volumes (MT)



\*Revenue figures are on Standalone basis

Hydrogenation is a chemical reaction between molecular hydrogen (H<sub>2</sub>) and another compound or element, usually in the presence of a catalyst.

- The company has manufacturing facilities in Jhagadia for Hydrogenation. The first unit (also named as Unit 1) has a capacity of 27,000 MTPA which became a part of Valiant Organics through the amalgamation of Amarjyot Chemicals in 2019.
- It has also ventured into the manufacturing of 2 new products in FY21 of Ortho Anisidine (OA) and Para Anisidine (PA), as well as expanded the capacity of a couple of existing products.
- The company also does contract manufacturing for a few leading domestic clients for some key customized products from these plants.

**Para Amino Phenol (PAP) is an essential element in the synthesis of paracetamol.**

- PAP is a difficult product to make and is primarily an import substitute product in India.
- Due to the company's strong experience and significant efforts on R&D, as well as raw material security of PNCB from its group company, Aarti Industries Ltd, it became one of the first companies in India to commercialize the plant for manufacturing Para Amino Phenol (PAP) in FY21 in Jhagadia Unit 2 with a capacity of 12,000 MTPA.
- Being a difficult product to manufacture, the company is currently focusing on achieving process consistencies and expect ramp of production in FY23.
- Majority of its PAP production will be sold to Valiant Laboratories Ltd, which is the subsidiary of the company.

### Key Products:


- Ortho Anisidine
- Para Anisidine
- IPPCA
- Meta Chloro Aniline
- Ortho Amino Phenol
- Para Amino Phenol

### Industries Served:


- Dyes
- Pigments
- Pharmaceuticals
- Agro Chemicals

*\*Revenue figures are on Standalone basis*

### Revenues (INR Mn)\*



### Sales Volumes (MT)



## Acetylation

Acetylation is a chemical reaction which introduces an acetyl functional group into a chemical compound.

- The acetylation procedure is carried out at the company's Ahmedabad facility which has a capacity of 1,800 MTPA
- The key product under this segment is '6 Acetyl Ortho Aminophenol Para Sulfonic Acid', which finds its usage in dye intermediates.
- Valiant also does job work and helps in multiple conversions on annual contracts.

## Sulphonation


Sulfonation is an organic reaction in which a hydrogen atom on an arene is replaced by a sulfonic acid functional group in an electrophilic aromatic substitution.

- Like acetylation, the sulphonation procedure is also carried out at the company's Ahmedabad facility.
- The products Ortho Toluidine 5 Sulfonic Acid (OT5SA), 2-Amino-5-Methyl benzenesulfonic Acis (4B Acid), & 2-Amino-4-Chloro-5 Methyl Benzenesulfonic Acid (2B Acid) are used as dye and pigment intermediaries.


## Methoxylation

- The products, Ortho Nitro Anisole (ONA) & Para Nitro Anisole (PNA) are being captively consumed to manufacture Ortho Anisidine (OA) and Para Anisidine (PA).
- This process is being carries out along with hydrogenation at Unit 1 of the Jhagadia facility.


### Revenues (INR Mn)\*



### Sales Volumes (MT)




\*Revenue figures are on Standalone basis




# INDUSTRY OVERVIEW

- **Expansive Product Portfolio:** India's chemical landscape is vast, boasting over 80,000 commercial products, offering a diverse array of solutions to global demands.
- **Global Manufacturing Powerhouse:** Positioned as the 6th largest manufacturer of chemicals worldwide and the 3rd largest in Asia, India commands a significant presence on the global stage.
- **Staggering Growth Trajectory:** The Indian chemical industry, valued at USD 178 billion in FY 2019-20, is poised for meteoric growth, projected to soar to USD 300 billion by 2024-25 and an impressive USD 1 trillion by 2040.
- **Dominance in Specialty Chemicals:** With the Asia Pacific region commanding nearly half of the global specialty chemicals market, India stands as a dominant force, expected to elevate its share to 4% by 2027, catalyzing further industry expansion.
- **Surpassing Projections:** Forecasts indicate that India's specialty chemicals market will outpace China, with a projected market share of 6% by 2026, fueled by a robust surge in domestic demand and export prowess.
- **Investment Surge:** A resurgence in domestic demand coupled with robust export performance is propelling a remarkable 50% year-on-year increase in capex for specialty chemicals manufacturers, reaching INR 6,000-6,200 Crs (USD 815-842 Mn) in FY22.
- **Rising Domestic Demand:** Anticipated growth in domestic demand signals a monumental shift, with projections soaring from USD 170-180 billion in 2021 to an impressive USD 850-1,000 billion by 2040.
- **Global Trade Leadership:** India's prowess in global chemical trade is undeniable, ranking 14th in exports and 8th in imports worldwide (excluding pharmaceuticals), underlining its pivotal role in global supply chains.
- **Disruption Spurs Opportunity:** Supply disruptions in China have catalyzed a strategic shift in global end-user industries towards Indian players, underscoring India's resilience and reliability as a preferred partner.
- **Government Support:** Recognizing the industry's pivotal role, the government has allocated INR 209crs (USD 27.43 million) in the Union Budget for 2022-23, reaffirming its commitment to fostering growth and innovation.
- **Driving Global Innovations:** India and China's prominence in dye production presents a promising avenue for printing inks applications across the Asia Pacific, with India contributing significantly to global dye production.
- **Agrochemical Advancements:** A cornerstone of India's chemical sector, agrochemicals drive substantial revenue, with 50% of production earmarked for exports, highlighting India's pivotal role in global agricultural sustainability.
- **Insecticides share:** 53% of the total domestic agrochemicals market, followed by Herbicides.

Global Chemical Market (USD Bn)




Indian Chemical Market (USD Bn)





## GROWING DEMAND

- Rise in demand from end-users Industries such as food processing, personal care & home care is driving development of different segments in India's specialty chemical market.
- Chemicals and petrochemicals demand in India is expected to nearly triple and reach USD 1 trillion by 2040
- India is the 6th largest producer of chemicals in the world and 3rd in Asia, contributing 7% to India's GDP.



## OPPORTUNITIES

- Supply disruption in China has caused the global end-user industries to diversify their vendor base mainly towards Indian players.
- Closure of plants in the EU and China due to increasing environmental concerns have favoured Indian manufacturers to invest further in specialty chemicals.
- With Global companies seeking to de-risk their supply chains, which are dependent on China, the chemical sector in India has the opportunity for a significant growth



## POLICY SUPPORT

- The government plans to implement a production-link incentive system with 10-20% output incentives for the agrochemical sector; to create an end-to-end manufacturing ecosystem through the growth of clusters.
- In Union Budget for 2022-23, government allocated INR 209crs (USD 27.43 million) to the chemical sector.



## INCREASING INVESTMENT

- FDI inflows in the chemicals sector (other than fertilizers) reached USD 22.07 billion between April 2000-December 2023.
- An investment of INR 8 lakh crore (USD 107.38 billion) is estimated in the Indian chemicals and petrochemicals sector by 2025.
- Prime Minister, Mr. Narendra Modi, laid the foundation stone of development projects worth more than INR 50,700 crore (USD 6.11 billion) on September 14, 2023.



# FINANCIAL OVERVIEW

# Historical Consolidated Income Statement

| Particulars (INR Mn)   | FY21          | FY22          | FY23          | FY24           |
|--|---------------|---------------|---------------|----------------|
| Revenue from Operations  | 7,548         | 11,533        | 10,518        | 7,231          |
| Total Expenses   | 5,496         | 9,484         | 8,875         | 6,849          |
| EBITDA   | 2,052         | 2,049         | 1,643         | 382            |
| <i>EBITDA Margins (%)</i>  | <i>27.19%</i> | <i>17.77%</i> | <i>15.62%</i> | <i>5.28%</i>   |
| Other Income   | 59            | 74            | 80            | 93             |
| Depreciation   | 212           | 296           | 292           | 349            |
| Finance Cost   | 50            | 65            | 108           | 163            |
| Profit Before Exceptional Items & Share of Profit/(Loss) of Associates | 1,849         | 1,762         | 1,323         | (37)           |
| Exceptional Items  | -             | -             | 49            | (34)           |
| Share of Profit/(Loss) of Associates                                   | -             | -             | -             | (16)           |
| PBT  | 1,849         | 1,762         | 1,372         | (87)           |
| Tax  | 540           | 483           | 346           | (3)            |
| PAT  | 1,309         | 1,279         | 1,026         | (84)           |
| <i>PAT Margins (%)</i>   | <i>17.34%</i> | <i>11.09%</i> | <i>9.75%</i>  | <i>(1.16)%</i> |
| Other Comprehensive Income   | 69            | 6             | 1             | 7              |
| Total Comprehensive Income   | 1,378         | 1,285         | 1,027         | (77)           |
| Basic/Diluted EPS (INR)  | 40.97         | 40.51         | 31.50         | (3.00)         |

\*FY21 onward figures as per Ind AS

# Consolidated Balance Sheet

| Particulars (INR Mn)                           | FY22          | FY23          | FY24          |
|--|---------------|---------------|---------------|
| <b>EQUITY</b>                                  | <b>6,489</b>  | <b>7,401</b>  | <b>7,293</b>  |
| a) Equity Share Capital                        | 272           | 272           | 276           |
| b) Other Equity                                | 5,856         | 6,616         | 7,017         |
| c) Optionally Convertible Preference Shares    | 4             | 4             | -             |
| d) Non Controlling Interest                    | 357           | 509           | -             |
| <b>LIABILITIES</b>                             |               |               |               |
| <b>Non-Current Liabilities</b>                 | <b>1,340</b>  | <b>1,064</b>  | <b>1,055</b>  |
| Financial Liabilities                          |               |               |               |
| a) Borrowings                                  | 1,058         | 706           | 742           |
| b) Lease Liabilities                           | 5             | 11            | 2             |
| c) Provisions                                  | 11            | 15            | 19            |
| d) Deferred Tax Liabilities (Net)              | 266           | 332           | 292           |
| <b>Current Liabilities</b>                     | <b>4,092</b>  | <b>3,927</b>  | <b>4,132</b>  |
| a) Financial Liabilities                       |               |               |               |
| (i) Borrowings                                 | 2,568         | 2,018         | 1,823         |
| (ii) Trade Payables                            | 1,312         | 1,656         | 2,074         |
| (iii) Other Financial Liabilities              | 161           | 200           | 173           |
| (iv) Lease Liabilities                         | 3             | 2             | 2             |
| b) Other Current Liabilities                   | 24            | 21            | 23            |
| c) Provisions                                  | 24            | 30            | 37            |
| <b>GRAND TOTAL - EQUITIES &amp; LIABILITES</b> | <b>11,921</b> | <b>12,392</b> | <b>12,480</b> |

| Particulars (INR Mn)               | FY22          | FY23          | FY24          |
|------------------------------------|---------------|---------------|---------------|
| <b>Non-Current Assets</b>          | <b>6,652</b>  | <b>7,682</b>  | <b>8,352</b>  |
| a) Property, Plant and Equipment   | 5,303         | 6,565         | 6,297         |
| c) Right-Of-Use Assets             | 8             | 12            | 5             |
| b) Capital Work In Progress        | 1,116         | 709           | 861           |
| d) Other Intangible Assets         | -             | 2             | 2             |
| e) Goodwill on Consolidation       | 123           | 123           | 123           |
| f) Financial Assets                |               |               |               |
| (i) Investments                    | 33            | 37            | 953           |
| (iii) Other Financial Assets       | 58            | 68            | 54            |
| g) Other Non-Current assets        | 11            | 166           | 57            |
| <b>Current Assets</b>              | <b>5,269</b>  | <b>4,710</b>  | <b>4,128</b>  |
| a) Inventories                     | 1,136         | 1,262         | 1,142         |
| b) Financial Assets                |               |               |               |
| (i) Investments                    | 46            | 375           | 33            |
| (ii) Trade Receivables             | 3,209         | 2,543         | 2,094         |
| (iii) Cash and Cash Equivalentents | 250           | 78            | 35            |
| (iv) Other Bank balances           | 203           | 4             | 3             |
| (v) Loans                          | 5             | 8             | 492           |
| (vi) Other financial assets        | 11            | 36            | 29            |
| c) Other Current Assets            | 300           | 308           | 173           |
| d) Current Tax Assets (Net)        | 109           | 96            | 127           |
| <b>GRAND TOTAL – ASSETS</b>        | <b>11,921</b> | <b>12,392</b> | <b>12,480</b> |

\*FY21 onward figures as per Ind AS

# Historical Standalone Income Statement

| Particulars (INR Mn)                 | FY21          | FY22          | FY23          | FY24           |
|--------------------------------------|---------------|---------------|---------------|----------------|
| Revenue from Operations              | 5,742         | 9,484         | 9,116         | 6,772          |
| Total Expenses                       | 4,170         | 7,811         | 7,817         | 6,376          |
| EBITDA                               | 1,572         | 1,673         | 1,299         | 396            |
| <i>EBITDA Margins (%)</i>            | <i>27.38%</i> | <i>17.64%</i> | <i>14.25%</i> | <i>5.85%</i>   |
| Other Income                         | 169           | 33            | 29            | 29             |
| Depreciation                         | 186           | 273           | 276           | 340            |
| Finance Cost                         | 35            | 64            | 105           | 194            |
| <b>PBT (Excl. Exceptional Items)</b> | <b>1,520</b>  | <b>1,369</b>  | <b>947</b>    | <b>(109)</b>   |
| Exceptional Items                    | -             | -             | 49            | 58             |
| <b>PBT</b>                           | <b>1,520</b>  | <b>1,369</b>  | <b>996</b>    | <b>(51)</b>    |
| Tax                                  | 374           | 340           | 240           | (21)           |
| <b>Profit After Tax</b>              | <b>1,146</b>  | <b>1,029</b>  | <b>756</b>    | <b>(30)</b>    |
| <i>PAT Margins (%)</i>               | <i>19.96%</i> | <i>10.85%</i> | <i>8.29%</i>  | <i>(0.44)%</i> |
| Other Comprehensive Income           | 69            | 8             | (11)          | 7              |
| <b>Total Comprehensive Income</b>    | <b>1,215</b>  | <b>1,037</b>  | <b>745</b>    | <b>(23)</b>    |
| Diluted EPS (INR per share)          | 40.98         | 36.81         | 27.02         | (1.09)         |

\*FY21 onward figures as per Ind AS

# Standalone Balance Sheet


| Particulars (INR Mn)                           | FY22          | FY23          | FY24          |
|--|---------------|---------------|---------------|
| <b>EQUITY</b>                                  | <b>6,031</b>  | <b>6,661</b>  | <b>6,649</b>  |
| a) Equity Share Capital                        | 272           | 272           | 276           |
| b) Other Equity                                | 5,755         | 6,385         | 6,373         |
| c) Optionally Convertible Preference Shares    | 4             | 4             | -             |
| <b>LIABILITIES</b>                             |               |               |               |
| <b>Non-Current Liabilities</b>                 | <b>1,215</b>  | <b>932</b>    | <b>1,055</b>  |
| Financial Liabilities                          |               |               |               |
| a) Borrowings                                  | 940           | 589           | 742           |
| b) Lease Liabilities                           | 2             | 2             | 2             |
| c) Provisions                                  | 10            | 15            | 19            |
| d) Deferred Tax Liabilities (Net)              | 263           | 326           | 292           |
| e) Other Non-Current Liabilities               | -             | -             | -             |
| <b>Current Liabilities</b>                     | <b>3,583</b>  | <b>3,465</b>  | <b>3,719</b>  |
| a) Financial Liabilities                       |               |               |               |
| (i) Borrowings                                 | 2,110         | 1,602         | 1,410         |
| (ii) Trade Payables                            | 1,271         | 1,643         | 2,074         |
| (iii) Other Financial Liabilities              | 154           | 179           | 173           |
| (iv) Lease Liabilities                         | 2             | 2             | 2             |
| b) Other Current Liabilities                   | 22            | 11            | 23            |
| c) Provisions                                  | 24            | 28            | 37            |
| d) Current Tax Liabilities (Net)               | -             | -             | -             |
| <b>GRAND TOTAL - EQUITIES &amp; LIABILITES</b> | <b>10,829</b> | <b>11,058</b> | <b>11,423</b> |

| Particulars (INR Mn)             | FY22          | FY23          | FY24          |
|----------------------------------|---------------|---------------|---------------|
| <b>Non-Current Assets</b>        | <b>6,787</b>  | <b>7,424</b>  | <b>7,818</b>  |
| a) Property, Plant and Equipment | 5,085         | 6,092         | 6,297         |
| b) Right-Of-Use Assets           | 4             | 4             | 5             |
| c) Capital Work In Progress      | 1,102         | 702           | 861           |
| d) Other Intangible Assets       | -             | 2             | 2             |
| e) Financial Assets              |               |               |               |
| (i) Investments in Subsidiaries  | 501           | 489           | 489           |
| (ii) Other Investments           | 32            | 37            | 53            |
| (iii) Loans                      | 52            | 55            | 54            |
| f) Other Non-Current assets      | 11            | 43            | 57            |
| <b>Current Assets</b>            | <b>4,042</b>  | <b>3,634</b>  | <b>3,605</b>  |
| a) Inventories                   | 973           | 1,137         | 1,142         |
| b) Financial Assets              |               |               |               |
| (i) Investments                  | 1             | 2             | -             |
| (ii) Trade Receivables           | 2,532         | 2,118         | 2,094         |
| (iii) Cash and Cash Equivalents  | 230           | 63            | 33            |
| (iv) Other Bank balances         | 3             | 3             | 3             |
| (v) Loans                        | 5             | 7             | 6             |
| (vi) Other financial assets      | 3             | 29            | 29            |
| c) Other Current Assets          | 217           | 198           | 171           |
| d) Current Tax Assets (Net)      | 78            | 77            | 127           |
| <b>GRAND TOTAL – ASSETS</b>      | <b>10,829</b> | <b>11,058</b> | <b>11,423</b> |


\*FY21 onward figures as per Ind AS

# Consolidated Financial Highlights


Operational Revenue (INR Mn)




EBITDA (INR Mn) & EBITDA Margins (%)




PAT (INR Mn) & PAT Margins (%)




Net Debt to Equity (x)




Net Worth (INR Mn)



Return on Capital Employed & Return on Equity (%)




### Share Price up to 31st March, 2024



| Price Data (As on 31 <sup>st</sup> March, 2024) | INR           |
|---|---------------|
| Face Value                                      | 10.00         |
| Market Price                                    | 379.80        |
| 52 Week H/L                                     | 635.20/373.95 |
| Market Cap (Mn)                                 | 10,473.00     |
| Equity Shares Outstanding (Mn)                  | 27.58         |
| 1 Year Avg Trading Volume ('000)                | 13.90         |

### Shareholding pattern (As on 31<sup>st</sup> March, 2024)



## **Valiant Organics Limited**

*No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Valiant Organics Limited ("Company"), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.*

*Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.*

*This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.*

*This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.*

## **Valorem Advisors Disclaimer:**

*Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.*

*Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.*



**For further details please contact our Investor Relations Representatives:**

**VALOREM ADVISORS**

**Mr. Anuj Sonpal**

Tel: +91-22-49039500

Email: [valiant@valoremadvisors.com](mailto:valiant@valoremadvisors.com)



**THANK YOU**